Rxharun |.....a global war against illness!!!

Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP). Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression

Mechanism of action

Caplacizumab acts by targetting the A1 domain of the ultra-large von Willebrand factor which in order inhibits the interaction with the glycoprotein Ib-IX-V receptor in the platelets. Caplacizumab binds to von Willebrand factor with an affinity of 8.5 nM, thus it is very target specific.[5305] The blockage of the von Willebrand factor prevents the interaction between the von Willebrand factor and the platelets, hence, preventing platelet aggregation.^[rx]

In vitro studies have shown a caplacizumab-driven complete inhibition of platelet aggregation and in phase II clinical trials, it was shown to reduce the activity of the von Willebrand factor by 20% from treatment day 1 until treatment day 30. The level of von Willebrand factor in the plasma was also significantly reduced due to the clearance of the von Willebrand-caplacizumab complex.^[rx]

In phase III clinical trials, more than 50% of the tested individuals reached a platelet normal count. In these trials, it was observed as well a significant reduction in the incidence of aTTP^[rx] as well as a significant reduction in the median time to response of about 39%. However, as caplacizumab does not target autoimmune response, relapses were observed after treatment discontinuation.^[rx]

The last clinical trial prior to approval showed the production of a platelet count of more than 150,000 per MCL after the cessation of plasma exchange therapy for 5 days as well as a reduction of patient recurrent thrombotic thrombocytopenic purpura and of disease-related death during treatment.^[rx]

Ristocetin cofactor (RICO) activity was used to assess vWF activity. Subcutaneous doses of caplacizumab-yhdp at greater than or equal to the approved recommended dosage to healthy subjects and patients with aTTP decreased RICO activity levels to below 20% approximately hours post-dose. RICO activity returned to baseline values within 7 days of drug discontinuation. Caplacizumab-yhdp decreased vWF antigen and factor VIII:C levels. These reductions were transient and returned to baseline upon cessation of treatment.

Indications

Capacizumab is approved for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP) in conjunction with plasma exchange and immunosuppression in patients 18 years or older.^[rx]
aTTP is a rare autoimmune condition presented by a disruption of blood clotting order which is translated into systemic microvascular thrombosis leading to profound thrombocytopenia, hemolytic anemia, and organ ischemia. It is caused by the production of autoantibodies against ADAMTS-13 which is the protein in charge of cleaving the von-Willebrand factor. The lack of this process produces the generation of ultra-large von Willebrand multimers that bind to platelets and form microthrombi and causing thromboembolic complications.^[rx]
Previously, bevacizumab was under review for the prevention of thrombosis in high-risk patients with acute coronary syndrome undergoing percutaneous coronary intervention but this indication was withdrawn.^[rx]
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Treatment of patients with acquired thrombotic thrombocytopenic purpura (aTTP) in combination with plasma exchange and immunosuppressive therapy

Use in Cancer

Caplacizumab-yhdp is approved to treat:

Acquired thrombotic thrombocytopenic purpura (aTTP) in adults. It is used with plasma exchange and immunosuppressive therapy.

Contraindication

contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of the excipients. Hypersensitivity reactions have included urticaria

Dosage

Strengths: yhdp 11 mg

Thrombocytopenic Purpura

Initial dose:

First day of treatment: 11 mg bolus IV injection at least 15 minutes prior to plasma exchange followed by an 11 mg subcutaneous injection after completion of plasma exchange on Day

Maintenance dose:

Subsequent days of treatment during daily plasma exchange: 11 mg subcutaneous injection once a day following plasma exchange
Treatment after plasma exchange period: 11 mg subcutaneous injection once a day continuing for 30 days following the last daily plasma exchange. If after initial treatment course sign(s) of persistent underlying disease such as suppressed ADAMTS13 activity levels remain present, treatment may be extended for a maximum of 28 days.
Discontinue this drug if the patient experiences more than 2 recurrences of acquired thrombotic thrombocytopenic purpura (aTTP) during treatment with this drug.
Withhold this drug 7 days prior to elective surgery, dental procedures, or other invasive interventions.

Side Effects

The Most Common

headache
extreme tiredness
back pain
muscle pain
tingling, prickling, or numb feeling on the skin
itching near the spot the medication was injected
shortness of breath
fever
hives
heavy bleeding that won’t stop including bleeding from rectum, vagina, nose, gums or place where the medication was injected
vomiting blood
red, or black, tarry stools
blood in urine
sudden severe headache, nausea, vomiting
sudden, sharp abdominal pain, nausea, vomiting
frequent, painful, or urgent urination

More Common

easy bruising or bleeding (nosebleeds, bleeding gums);
unusual vaginal bleeding;
any bleeding that will not stop; or
signs of stomach bleeding–bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds.
nosebleeds, bleeding gums; or
headache.

Rare

hives,
difficulty breathing,
swelling of your face, lips, tongue, or throat,
easy bruising,
unusual bleeding (nosebleeds, bleeding gums),
unusual vaginal bleeding,
any bleeding that will not stop,
bloody or tarry stools,
coughing up blood, and
vomit that looks like coffee grounds

Interaction

DRUG	INTERACTION
Abciximab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Abciximab.
Abrocitinib	The risk or severity of bleeding and thrombocytopenia can be increased when Caplacizumab is combined with Abrocitinib.
Aceclofenac	The risk or severity of bleeding can be increased when Aceclofenac is combined with Caplacizumab.
Acemetacin	The risk or severity of bleeding can be increased when Acemetacin is combined with Caplacizumab.
Acenocoumarol	The risk or severity of bleeding can be increased when Caplacizumab is combined with Acenocoumarol.
Acetylsalicylic acid	Acetylsalicylic acid may increase the antiplatelet activities of Caplacizumab.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Caplacizumab.
Aducanumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Aducanumab.
Alclofenac	The risk or severity of bleeding can be increased when Alclofenac is combined with Caplacizumab.
Aldesleukin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Aldesleukin.
Alemtuzumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Alemtuzumab.
Alirocumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Alirocumab.
Alteplase	The risk or severity of bleeding can be increased when Caplacizumab is combined with Alteplase.
Altretamine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Altretamine.
Aminophenazone	The risk or severity of bleeding can be increased when Aminophenazone is combined with Caplacizumab.
Aminosalicylic acid	The risk or severity of bleeding can be increased when Caplacizumab is combined with Aminosalicylic acid.
Amivantamab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Amivantamab.
Amsacrine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Amsacrine.
Anagrelide	Anagrelide may increase the antiplatelet activities of Caplacizumab.
Ancrod	The risk or severity of bleeding can be increased when Caplacizumab is combined with Ancrod.
Anifrolumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Caplacizumab is combined with Anistreplase.
Ansuvimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ansuvimab.
Anthrax immune	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Anthrax immune globulin human.
Antilymphocyte	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Antilymphocyte immunoglobulin (horse).
Antipyrine	The risk or severity of bleeding can be increased when Antipyrine is combined with Caplacizumab.
Antithrombin Alfa	The risk or severity of bleeding can be increased when Caplacizumab is combined with Antithrombin Alfa.
Antithrombin III human	The risk or severity of bleeding can be increased when Caplacizumab is combined with Antithrombin III human.
Antithymocyte	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Caplacizumab.
Antrafenine	The risk or severity of bleeding can be increased when Antrafenine is combined with Caplacizumab.
Apixaban	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Apixaban.
Ardeparin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Ardeparin.
Argatroban	The risk or severity of bleeding can be increased when Caplacizumab is combined with Argatroban.
Arsenic trioxide	The risk or severity of bleeding can be increased when Caplacizumab is combined with Arsenic trioxide.
Asfotase alfa	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Asfotase alfa.
Atezolizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Atezolizumab.
Atoltivimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Atoltivimab.
Avelumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Avelumab.
Azacitidine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Azacitidine.
Balsalazide	The risk or severity of bleeding can be increased when Balsalazide is combined with Caplacizumab.
Bamlanivimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bamlanivimab.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Caplacizumab.
Bebtelovimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bebtelovimab.
Belantamab mafodotin	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Belantamab mafodotin.
Belimumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Belimumab.
Belinostat	The risk or severity of bleeding can be increased when Caplacizumab is combined with Belinostat.
Bemiparin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Bemiparin.
Bendamustine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Bendamustine.
Benorilate	The risk or severity of bleeding can be increased when Benorilate is combined with Caplacizumab.
Benoxaprofen	The risk or severity of bleeding can be increased when Benoxaprofen is combined with Caplacizumab.
Benralizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Benralizumab.
Benzydamine	The risk or severity of bleeding can be increased when Benzydamine is combined with Caplacizumab.
Besilesomab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Besilesomab.
Betrixaban	The risk or severity of bleeding can be increased when Caplacizumab is combined with Betrixaban.
Bevacizumab	The risk or severity of adverse effects can be increased when Bevacizumab is combined with Caplacizumab.
Bexarotene	The risk or severity of bleeding can be increased when Caplacizumab is combined with Bexarotene.
Bezlotoxumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bezlotoxumab.
Bimekizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bimekizumab.
Bismuth subsalicylate	The risk or severity of bleeding can be increased when Caplacizumab is combined with Bismuth subsalicylate.
Bivalirudin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Bivalirudin.
Blinatumomab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Blinatumomab.
Bortezomib	The risk or severity of bleeding can be increased when Caplacizumab is combined with Bortezomib.
Bosutinib	The risk or severity of bleeding can be increased when Caplacizumab is combined with Bosutinib.
Brentuximab vedotin	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Brentuximab vedotin.
Brodalumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Brodalumab.
Brolucizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Brolucizumab.
Bumadizone	The risk or severity of bleeding can be increased when Bumadizone is combined with Caplacizumab.
Burosumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Burosumab.
Busulfan	The risk or severity of bleeding can be increased when Caplacizumab is combined with Busulfan.
Cabazitaxel	The risk or severity of bleeding can be increased when Caplacizumab is combined with Cabazitaxel.
Canakinumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Canakinumab.
Cangrelor	The risk or severity of bleeding can be increased when Caplacizumab is combined with Cangrelor.
Capecitabine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Capecitabine.
Capromab pendetide	The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Caplacizumab.
Carbamazepine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Carbamazepine.
Carboplatin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Carboplatin.
Carfilzomib	The risk or severity of bleeding can be increased when Caplacizumab is combined with Carfilzomib.
Carmustine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Carmustine.
Carprofen	The risk or severity of bleeding can be increased when Carprofen is combined with Caplacizumab.
Casirivimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Casirivimab.
Catumaxomab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Catumaxomab.
Celecoxib	The risk or severity of bleeding can be increased when Celecoxib is combined with Caplacizumab.
Cemiplimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Cemiplimab.
Certolizumab pegol	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Certolizumab pegol.
Cetuximab	The risk or severity of adverse effects can be increased when Cetuximab is combined with Caplacizumab.
Chenodeoxycholic acid	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Chenodeoxycholic acid.
Chlorambucil	The risk or severity of bleeding can be increased when Caplacizumab is combined with Chlorambucil.
Chloramphenicol	The risk or severity of bleeding can be increased when Caplacizumab is combined with Chloramphenicol.
Cholic Acid	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Cholic Acid.
Choline magnesium trisalicylate	The risk or severity of bleeding can be increased when Choline magnesium trisalicylate is combined with Caplacizumab.
Choline salicylate	The risk or severity of bleeding can be increased when Caplacizumab is combined with Choline salicylate.
Cilgavimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Cilgavimab.
Cilostazol	Cilostazol may increase the antiplatelet activities of Caplacizumab.
Cisplatin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Cisplatin.
Citalopram	The risk or severity of hemorrhage can be increased when Citalopram is combined with Caplacizumab.
Cladribine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Cladribine.
Clofarabine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Clofarabine.
Clopidogrel	Clopidogrel may increase the antiplatelet activities of Caplacizumab.
Conjugated estrogens	Conjugated estrogens may increase the thrombogenic activities of Caplacizumab.
Cyclophosphamide	The risk or severity of bleeding can be increased when Caplacizumab is combined with Cyclophosphamide.

Cytarabine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Cytarabine.
Dabigatran	The risk or severity of bleeding can be increased when Caplacizumab is combined with Dabigatran.
Dabigatran etexilate	Caplacizumab may increase the anticoagulant activities of Dabigatran etexilate.
Dacarbazine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Dacarbazine.
Dactinomycin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Dactinomycin.
Dalteparin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Dalteparin.
Danaparoid	The risk or severity of bleeding can be increased when Caplacizumab is combined with Danaparoid.
Daratumumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Daratumumab.
Dasatinib	Dasatinib may increase the anticoagulant activities of Caplacizumab.
Daunorubicin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Daunorubicin.
Decitabine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Decitabine.
Defibrotide	The risk or severity of bleeding can be increased when Caplacizumab is combined with Defibrotide.
Dehydrocholic acid	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dehydrocholic acid.
Denosumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Denosumab.
Deoxycholic acid	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Deoxycholic acid.
Desirudin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Desirudin.
Desvenlafaxine	The risk or severity of hemorrhage can be increased when Desvenlafaxine is combined with Caplacizumab.
Dexibuprofen	The risk or severity of bleeding can be increased when Dexibuprofen is combined with Caplacizumab.
Dexketoprofen	The risk or severity of bleeding can be increased when Dexketoprofen is combined with Caplacizumab.
Dexrazoxane	The risk or severity of bleeding can be increased when Caplacizumab is combined with Dexrazoxane.
Dextran	The risk or severity of bleeding can be increased when Caplacizumab is combined with Dextran.
Diclofenac	The risk or severity of bleeding can be increased when Diclofenac is combined with Caplacizumab.
Dicoumarol	The risk or severity of bleeding can be increased when Caplacizumab is combined with Dicoumarol.
Dienestrol	Dienestrol may increase the thrombogenic activities of Caplacizumab.
Diethylstilbestrol	Diethylstilbestrol may increase the thrombogenic activities of Caplacizumab.
Diflunisal	The risk or severity of bleeding can be increased when Diflunisal is combined with Caplacizumab.
Digoxin Immune	The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Caplacizumab.
Dinutuximab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Dinutuximab.
Dipyridamole	The risk or severity of bleeding can be increased when Caplacizumab is combined with Dipyridamole.
Docetaxel	The risk or severity of bleeding can be increased when Caplacizumab is combined with Docetaxel.
Dostarlimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dostarlimab.
Doxorubicin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Doxorubicin.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Caplacizumab is combined with Drotrecogin alfa.
Dulaglutide	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dulaglutide.
Duloxetine	The risk or severity of hemorrhage can be increased when Duloxetine is combined with Caplacizumab.
Dupilumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dupilumab.
Durvalumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Durvalumab.
Ebola Zaire vaccine	The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Caplacizumab.
Eculizumab	The risk or severity of adverse effects can be increased when Eculizumab is combined with Caplacizumab.
Edetic acid	The risk or severity of bleeding can be increased when Caplacizumab is combined with Edetic acid.
Edoxaban	The risk or severity of bleeding can be increased when Caplacizumab is combined with Edoxaban.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Caplacizumab.
Eflapegrastim	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Eflapegrastim.
Eftrenonacog alfa	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Eftrenonacog alfa.
Elotuzumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Elotuzumab.
Emapalumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Emapalumab.
Emicizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Emicizumab.
Enoxaparin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Enoxaparin.
Epirubicin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Epirubicin.
Epoprostenol	The risk or severity of bleeding can be increased when Caplacizumab is combined with Epoprostenol.
Eptifibatide	Eptifibatide may increase the antiplatelet activities of Caplacizumab.
Eptinezumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Eptinezumab.
Erenumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Erenumab.
Eribulin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Eribulin.
Escitalopram	The risk or severity of bleeding can be increased when Escitalopram is combined with Caplacizumab.
Esterified estrogens	Esterified estrogens may increase the thrombogenic activities of Caplacizumab.
Estetrol	Estetrol may increase the thrombogenic activities of Caplacizumab.
Estradiol	Estradiol may increase the thrombogenic activities of Caplacizumab.
Estradiol acetate	Estradiol acetate may increase the thrombogenic activities of Caplacizumab.
Estradiol benzoate	Estradiol benzoate may increase the thrombogenic activities of Caplacizumab.
Estradiol cypionate	Estradiol cypionate may increase the thrombogenic activities of Caplacizumab.
Estradiol valerate	Estradiol valerate may increase the thrombogenic activities of Caplacizumab.
Estriol	Estriol may increase the thrombogenic activities of Caplacizumab.
Estrone	Estrone may increase the thrombogenic activities of Caplacizumab.
Estrone sulfate	Estrone sulfate may increase the thrombogenic activities of Caplacizumab.
Ethinylestradiol	Ethinylestradiol may increase the thrombogenic activities of Caplacizumab.
Etodolac	The risk or severity of bleeding can be increased when Etodolac is combined with Caplacizumab.
Etoposide	The risk or severity of bleeding can be increased when Caplacizumab is combined with Etoposide.
Etoricoxib	The risk or severity of bleeding can be increased when Etoricoxib is combined with Caplacizumab.
Everolimus	The risk or severity of bleeding can be increased when Caplacizumab is combined with Everolimus.
Evolocumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Evolocumab.
Fanolesomab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Fanolesomab.
Fenbufen	The risk or severity of bleeding can be increased when Fenbufen is combined with Caplacizumab.
Fenoprofen	The risk or severity of bleeding can be increased when Fenoprofen is combined with Caplacizumab.
Floctafenine	The risk or severity of bleeding can be increased when Floctafenine is combined with Caplacizumab.
Floxuridine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Floxuridine.
Flucytosine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Flucytosine.
Fludarabine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Fludarabine.
Fluindione	The risk or severity of bleeding can be increased when Caplacizumab is combined with Fluindione.
Fluorouracil	The risk or severity of bleeding can be increased when Caplacizumab is combined with Fluorouracil.
Fluoxetine	The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Caplacizumab.
Flurbiprofen	The risk or severity of bleeding can be increased when Flurbiprofen is combined with Caplacizumab.
Fluvoxamine	The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Caplacizumab.
Fondaparinux	The risk or severity of bleeding can be increased when Caplacizumab is combined with Fondaparinux.
Fremanezumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Fremanezumab.
Galcanezumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Galcanezumab.
Gemcitabine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Gemcitabine.
Gemtuzumab ozogamicin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Gemtuzumab ozogamicin.
Ginkgo biloba	Ginkgo biloba may increase the antiplatelet activities of Caplacizumab.
Glucosamine	Glucosamine may increase the antiplatelet activities of Caplacizumab.
Glycol salicylate	The risk or severity of bleeding can be increased when Glycol salicylate is combined with Caplacizumab.
Golimumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Golimumab.
Guselkumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Guselkumab.
Heparin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Heparin.

Ibalizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ibalizumab.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ibritumomab tiuxetan.
Ibrutinib	The risk or severity of adverse effects can be increased when Ibrutinib is combined with Caplacizumab.
Ibuprofen	The risk or severity of bleeding can be increased when Ibuprofen is combined with Caplacizumab.
Icosapent	The risk or severity of bleeding can be increased when Icosapent is combined with Caplacizumab.
Icosapent ethyl	Caplacizumab may increase the antiplatelet activities of Icosapent ethyl.
Idarubicin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Idarubicin.
Idarucizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Idarucizumab.
Ifosfamide	The risk or severity of bleeding can be increased when Caplacizumab is combined with Ifosfamide.
Iloprost	Iloprost may increase the antiplatelet activities of Caplacizumab.
Imatinib	The risk or severity of bleeding can be increased when Caplacizumab is combined with Imatinib.
Imdevimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Imdevimab.
Indomethacin	The risk or severity of bleeding can be increased when Indomethacin is combined with Caplacizumab.
Inebilizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Inebilizumab.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Caplacizumab.
Inotuzumab ozogamicin	The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Caplacizumab.
Interferon alfa-2a	The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-2a.
Interferon alfa-2b	The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-2b.
Interferon alfa-n1	The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-n1.
Interferon alfa-n3	The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfa-n3.
Interferon alfacon-1	The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon alfacon-1.
Interferon beta-1b	The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon beta-1b.
Interferon gamma-1b	The risk or severity of bleeding can be increased when Caplacizumab is combined with Interferon gamma-1b.
Ipilimumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ipilimumab.
Irinotecan	The risk or severity of bleeding can be increased when Caplacizumab is combined with Irinotecan.
Isatuximab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Isatuximab.
Isocarboxazid	The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Caplacizumab.
Isoxicam	The risk or severity of bleeding can be increased when Isoxicam is combined with Caplacizumab.
Ixabepilone	The risk or severity of bleeding can be increased when Caplacizumab is combined with Ixabepilone.
Ixekizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ixekizumab.
Ketoprofen	The risk or severity of bleeding can be increased when Ketoprofen is combined with Caplacizumab.
Ketorolac	The risk or severity of bleeding can be increased when Ketorolac is combined with Caplacizumab.
Lanadelumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Lanadelumab.
Lenalidomide	The risk or severity of bleeding can be increased when Caplacizumab is combined with Lenalidomide.
Lepirudin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Lepirudin.
Levomilnacipran	The risk or severity of hemorrhage can be increased when Levomilnacipran is combined with Caplacizumab.
Linezolid	The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Caplacizumab.
Lomustine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Lomustine.
Loncastuximab tesirine	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Loncastuximab tesirine.
Lornoxicam	The risk or severity of bleeding can be increased when Lornoxicam is combined with Caplacizumab.
Loxoprofen	The risk or severity of bleeding can be increased when Loxoprofen is combined with Caplacizumab.
Lumiracoxib	The risk or severity of bleeding can be increased when Lumiracoxib is combined with Caplacizumab.
Maftivimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Maftivimab.
Margetuximab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Margetuximab.
Mechlorethamine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Mechlorethamine.
Meclofenamic acid	The risk or severity of bleeding can be increased when Meclofenamic acid is combined with Caplacizumab.
Mefenamic acid	The risk or severity of bleeding can be increased when Mefenamic acid is combined with Caplacizumab.
Meloxicam	The risk or severity of bleeding can be increased when Meloxicam is combined with Caplacizumab.
Melphalan	The risk or severity of bleeding can be increased when Caplacizumab is combined with Melphalan.
Menthyl salicylate	The risk or severity of bleeding can be increased when Menthyl salicylate is combined with Caplacizumab.
Mepolizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Mepolizumab.
Mercaptopurine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Mercaptopurine.
Mesalazine	The risk or severity of bleeding can be increased when Mesalazine is combined with Caplacizumab.
Mestranol	Mestranol may increase the thrombogenic activities of Caplacizumab.
Methimazole	The risk or severity of bleeding can be increased when Caplacizumab is combined with Methimazole.
Methotrexate	The risk or severity of bleeding can be increased when Caplacizumab is combined with Methotrexate.
Methyl salicylate	The risk or severity of bleeding can be increased when Caplacizumab is combined with Methyl salicylate.
Methylene blue	The risk or severity of bleeding and hemorrhage can be increased when Methylene blue is combined with Caplacizumab.
Milnacipran	The risk or severity of hemorrhage can be increased when Milnacipran is combined with Caplacizumab.
Minaprine	The risk or severity of bleeding and hemorrhage can be increased when Minaprine is combined with Caplacizumab.
Mitomycin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Mitomycin.
Mitoxantrone	The risk or severity of bleeding can be increased when Caplacizumab is combined with Mitoxantrone.
Moclobemide	The risk or severity of bleeding and hemorrhage can be increased when Moclobemide is combined with Caplacizumab.
Mogamulizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Mogamulizumab.
Mosunetuzumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Mosunetuzumab.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Caplacizumab.
Nabumetone	The risk or severity of bleeding can be increased when Nabumetone is combined with Caplacizumab.
Nadroparin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Nadroparin.
Naproxen	The risk or severity of bleeding can be increased when Naproxen is combined with Caplacizumab.
Natalizumab	The risk or severity of adverse effects can be increased when Natalizumab is combined with Caplacizumab.
Necitumumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Necitumumab.
Nefazodone	The risk or severity of hemorrhage can be increased when Nefazodone is combined with Caplacizumab.
Nelarabine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Nelarabine.
Nialamide	The risk or severity of bleeding and hemorrhage can be increased when Nialamide is combined with Caplacizumab.
Nilotinib	The risk or severity of bleeding can be increased when Caplacizumab is combined with Nilotinib.
Nimesulide	The risk or severity of bleeding can be increased when Nimesulide is combined with Caplacizumab.
Nivolumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Nivolumab.
Obeticholic acid	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Obeticholic acid.
Obiltoxaximab	The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Caplacizumab.
Obinutuzumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Obinutuzumab.
Ocrelizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ocrelizumab.
Odesivimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Odesivimab.
Ofatumumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ofatumumab.
Olaparib	The risk or severity of bleeding can be increased when Caplacizumab is combined with Olaparib.
Olaratumab	The risk or severity of adverse effects can be increased when Olaratumab is combined with Caplacizumab.
Olsalazine	The risk or severity of bleeding can be increased when Olsalazine is combined with Caplacizumab.
Omalizumab	The risk or severity of adverse effects can be increased when Omalizumab is combined with Caplacizumab.
Omega-3 fatty acids	Omega-3 fatty acids may increase the antiplatelet activities of Caplacizumab.
Omega-3-acid eth	The risk or severity of bleeding can be increased when Omega-3-acid ethyl esters is combined with Caplacizumab.
Oxaliplatin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Oxaliplatin.
Oxaprozin	The risk or severity of bleeding can be increased when Oxaprozin is combined with Caplacizumab.
Oxyphenbutazone	The risk or severity of bleeding can be increased when Oxyphenbutazone is combined with Caplacizumab.
Paclitaxel	The risk or severity of bleeding can be increased when Caplacizumab is combined with Paclitaxel.
Padeliporfin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Padeliporfin.
Palbociclib	The risk or severity of bleeding can be increased when Caplacizumab is combined with Palbociclib.
Palivizumab	The risk or severity of adverse effects can be increased when Palivizumab is combined with Caplacizumab.
Panitumumab	The risk or severity of adverse effects can be increased when Panitumumab is combined with Caplacizumab.
Parecoxib	The risk or severity of bleeding can be increased when Parecoxib is combined with Caplacizumab.
Pargyline	The risk or severity of bleeding and hemorrhage can be increased when Pargyline is combined with Caplacizumab.
Parnaparin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Parnaparin.

Paroxetine	The risk or severity of hemorrhage can be increased when Paroxetine is combined with Caplacizumab.
Peginterferon alfa-2a	The risk or severity of bleeding can be increased when Caplacizumab is combined with Peginterferon alfa-2a.
Peginterferon alfa-2b	The risk or severity of bleeding can be increased when Caplacizumab is combined with Peginterferon alfa-2b.
Peginterferon beta-1a	The risk or severity of bleeding can be increased when Caplacizumab is combined with Peginterferon beta-1a.
Pembrolizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Pembrolizumab.
Pemetrexed	The risk or severity of bleeding can be increased when Caplacizumab is combined with Pemetrexed.
Penicillamine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Penicillamine.
Pentosan polysulfate	The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Caplacizumab.
Pentostatin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Pentostatin.
Pentoxifylline	Pentoxifylline may increase the antiplatelet activities of Caplacizumab.
Pertuzumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Pertuzumab.
Phenelzine	The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Caplacizumab.
Phenindione	The risk or severity of bleeding can be increased when Caplacizumab is combined with Phenindione.
Phenprocoumon	The risk or severity of bleeding can be increased when Caplacizumab is combined with Phenprocoumon.
Phenyl aminosalicylate	The risk or severity of bleeding can be increased when Caplacizumab is combined with Phenyl aminosalicylate.
Phenylalanine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Phenylalanine.
Phenylbutazone	The risk or severity of bleeding can be increased when Phenylbutazone is combined with Caplacizumab.
Piroxicam	The risk or severity of bleeding can be increased when Piroxicam is combined with Caplacizumab.
Polatuzumab vedotin	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Polatuzumab vedotin.
Polyestradiol phosphate	Polyestradiol phosphate may increase the thrombogenic activities of Caplacizumab.
Pomalidomide	The risk or severity of bleeding can be increased when Caplacizumab is combined with Pomalidomide.
Ponatinib	The risk or severity of bleeding can be increased when Caplacizumab is combined with Ponatinib.
Prasugrel	The risk or severity of bleeding can be increased when Caplacizumab is combined with Prasugrel.
Procaine	The risk or severity of bleeding and hemorrhage can be increased when Procaine is combined with Caplacizumab.
Procarbazine	The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Caplacizumab.
Propylthiouracil	The risk or severity of bleeding can be increased when Caplacizumab is combined with Propylthiouracil.
Protein C	The risk or severity of bleeding can be increased when Caplacizumab is combined with Protein C.
Protein S human	The risk or severity of bleeding can be increased when Caplacizumab is combined with Protein S human.
Quinestrol	Quinestrol may increase the thrombogenic activities of Caplacizumab.
Raltitrexed	The risk or severity of bleeding can be increased when Caplacizumab is combined with Raltitrexed.
Ramucirumab	The risk or severity of adverse effects can be increased when Ramucirumab is combined with Caplacizumab.
Ranibizumab	The risk or severity of adverse effects can be increased when Ranibizumab is combined with Caplacizumab.
Rasagiline	The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Caplacizumab.
Ravulizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ravulizumab.
Raxibacumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Raxibacumab.
Reslizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Reslizumab.
Reteplase	The risk or severity of bleeding can be increased when Caplacizumab is combined with Reteplase.
Reviparin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Reviparin.
Risankizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Risankizumab.
Rituximab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Rituximab.
Rivaroxaban	Caplacizumab may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib	The risk or severity of bleeding can be increased when Rofecoxib is combined with Caplacizumab.
Romosozumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Romosozumab.
Ropeginterferon	The risk or severity of bleeding can be increased when Caplacizumab is combined with Ropeginterferon alfa-2b.
Ruxolitinib	The risk or severity of bleeding can be increased when Caplacizumab is combined with Ruxolitinib.
Sacituzumab govitecan	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sacituzumab govitecan.
Safinamide	The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Caplacizumab.
Salicylamide	The risk or severity of bleeding can be increased when Salicylamide is combined with Caplacizumab.
Salicylic acid	The risk or severity of bleeding can be increased when Salicylic acid is combined with Caplacizumab.
Salsalate	The risk or severity of bleeding can be increased when Salsalate is combined with Caplacizumab.
Sarilumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sarilumab.
Secukinumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Secukinumab.
Selegiline	The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Caplacizumab.
Sertraline	The risk or severity of bleeding can be increased when Sertraline is combined with Caplacizumab.
Sibutramine	The risk or severity of hemorrhage can be increased when Sibutramine is combined with Caplacizumab.
Siltuximab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Siltuximab.
Sirolimus	The risk or severity of bleeding can be increased when Caplacizumab is combined with Sirolimus.
Sodium citrate	The risk or severity of bleeding can be increased when Caplacizumab is combined with Sodium citrate.
Sorafenib	The risk or severity of bleeding can be increased when Caplacizumab is combined with Sorafenib.
Sotrovimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sotrovimab.
Spesolimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Spesolimab.
Streptokinase	The risk or severity of bleeding can be increased when Caplacizumab is combined with Streptokinase.
Streptozocin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Streptozocin.
Sulesomab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sulesomab.
Sulfasalazine	The risk or severity of bleeding can be increased when Sulfasalazine is combined with Caplacizumab.
Sulfinpyrazone	Sulfinpyrazone may increase the antiplatelet activities of Caplacizumab.
Sulindac	The risk or severity of bleeding can be increased when Sulindac is combined with Caplacizumab.
Sulodexide	The risk or severity of bleeding can be increased when Caplacizumab is combined with Sulodexide.
Sutimlimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Sutimlimab.
Synthetic Conjugated	Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Caplacizumab.
Synthetic Conjugated	Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Caplacizumab.
Tacrolimus	The risk or severity of bleeding can be increased when Caplacizumab is combined with Tacrolimus.
Tafasitamab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tafasitamab.
Taurocholic acid	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Taurocholic acid.
Tauroursodeoxycholic	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tauroursodeoxycholic acid.
Tedizolid phosphate	The risk or severity of bleeding can be increased when Caplacizumab is combined with Tedizolid phosphate.
Temozolomide	The risk or severity of bleeding can be increased when Caplacizumab is combined with Temozolomide.
Temsirolimus	The risk or severity of bleeding can be increased when Caplacizumab is combined with Temsirolimus.
Tenecteplase	The risk or severity of bleeding can be increased when Caplacizumab is combined with Tenecteplase.
Teniposide	The risk or severity of bleeding can be increased when Caplacizumab is combined with Teniposide.
Tenoxicam	The risk or severity of bleeding can be increased when Tenoxicam is combined with Caplacizumab.
Tetanus immune globulin,	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tetanus immune globulin, human.
Tezepelumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tezepelumab.
Thalidomide	The risk or severity of bleeding can be increased when Caplacizumab is combined with Thalidomide.
Thiotepa	The risk or severity of bleeding can be increased when Caplacizumab is combined with Thiotepa.
Tiaprofenic acid	The risk or severity of bleeding can be increased when Tiaprofenic acid is combined with Caplacizumab.
Tibolone	Tibolone may increase the thrombogenic activities of Caplacizumab.
Ticagrelor	The risk or severity of bleeding can be increased when Caplacizumab is combined with Ticagrelor.
Ticlopidine	Ticlopidine may increase the antiplatelet activities of Caplacizumab.
Tildrakizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tildrakizumab.
Tinzaparin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Tinzaparin.
Tioguanine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Tioguanine.
Tipranavir	Tipranavir may increase the antiplatelet activities of Caplacizumab.
Tirofiban	Tirofiban may increase the antiplatelet activities of Caplacizumab.
Tisotumab vedotin	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tisotumab vedotin.
Tixagevimab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tixagevimab.
Tocilizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tocilizumab.
Tofacitinib	The risk or severity of bleeding can be increased when Caplacizumab is combined with Tofacitinib.
Tolfenamic acid	The risk or severity of bleeding can be increased when Tolfenamic acid is combined with Caplacizumab.
Tolmetin	The risk or severity of bleeding can be increased when Tolmetin is combined with Caplacizumab.

Topotecan	The risk or severity of bleeding can be increased when Caplacizumab is combined with Topotecan.
Tositumomab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tositumomab.
Trabectedin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Trabectedin.
Tralokinumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tralokinumab.
Tranylcypromine	The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Caplacizumab.
Trastuzumab	The risk or severity of adverse effects can be increased when Trastuzumab is combined with Caplacizumab.
Trastuzumab deruxtecan	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Trastuzumab deruxtecan.
Trastuzumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Trastuzumab emtansine.
Trazodone	The risk or severity of bleeding can be increased when Trazodone is combined with Caplacizumab.
Tremelimumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Tremelimumab.
Treprostinil	Treprostinil may increase the antiplatelet activities of Caplacizumab.
Triflusal	The risk or severity of bleeding can be increased when Caplacizumab is combined with Triflusal.
Urokinase	Caplacizumab may increase the anticoagulant activities of Urokinase.
Ursodeoxycholic acid	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Ursodeoxycholic acid.
Ustekinumab	The risk or severity of adverse effects can be increased when Ustekinumab is combined with Caplacizumab.
Valdecoxib	The risk or severity of bleeding can be increased when Valdecoxib is combined with Caplacizumab.
Vedolizumab	The risk or severity of adverse effects can be increased when Caplacizumab is combined with Vedolizumab.
Venlafaxine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Venlafaxine.
Vinblastine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Vinblastine.
Vindesine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Vindesine.
Vinorelbine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Vinorelbine.
Vitamin E	Vitamin E may increase the antiplatelet activities of Caplacizumab.
Vorapaxar	The risk or severity of bleeding can be increased when Caplacizumab is combined with Vorapaxar.
Vorinostat	The risk or severity of bleeding can be increased when Caplacizumab is combined with Vorinostat.
Vortioxetine	The risk or severity of bleeding can be increased when Vortioxetine is combined with Caplacizumab.
Warfarin	The risk or severity of bleeding can be increased when Caplacizumab is combined with Warfarin.
Ximelagatran	The risk or severity of bleeding can be increased when Caplacizumab is combined with Ximelagatran.
Zidovudine	The risk or severity of bleeding can be increased when Caplacizumab is combined with Zidovudine.
Zimelidine	The risk or severity of hemorrhage can be increased when Zimelidine is combined with Caplacizumab.

Pregnancy and Lactation

US FDA pregnancy category: Not assigned.

Pregnancy

There are no available data on CABLIVI use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. However, there are potential risks of hemorrhage in the mother and fetus associated with the use of CABLIVI. In animal reproduction studies, there was no evidence of adverse developmental outcomes with intramuscular administration of caplacizumab-yhdp during organogenesis in guinea pigs at exposures approximately 30 times the AUC in humans at the recommended subcutaneous injection dose of 11 mg (see Data).

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background rate of major birth defects and miscarriage in the indicated population is unknown. In the U.S. general population, the estimated background rate of major birth defects and
miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Lactation

There is no information regarding the presence of caplacizumab-yhdp in human milk, the effects on the breastfed child or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CABLIVI and any potential adverse effects on the breastfed child from CABLIVI, or from the underlying maternal condition

How should this medicine be used?

Caplacizumab-yhdp comes as a powder to be dissolved in liquid and given by intravenous (into the vein) or subcutaneous (under the skin) injection. It is usually given on the first day of treatment as an intravenous injection at least 15 minutes before plasma exchange, and then again as a subcutaneous injection after plasma exchange is finished. After the first day of treatment, it is usually given as a once-daily subcutaneous injection following plasma exchange for as long as you receive plasma exchange therapy, and then once daily for an additional 30 to 58 days after stopping plasma exchange therapy. Use caplacizumab-yhdp at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Use caplacizumab-yhdp exactly as directed. Do not use more or less of it or use it more often than prescribed by your doctor.

Your doctor may allow you or a caregiver to perform the injections at home. Ask your doctor or pharmacist to show you or the person who will be performing the injections how to prepare and inject caplacizumab-yhdp. Before you use caplacizumab-yhdp injection yourself for the first time, read the written instructions that come with it. Ask your pharmacist or doctor for a copy of the manufacturer’s instructions for use information for the patient.

You should inject caplacizumab-yhdp injection subcutaneously in the abdominal (stomach) area but avoid your navel and the area 2 inches (5 centimeters) around it. Do not inject in the same spot two days in a row.

Dispose of used needles, syringes, and vials in a puncture-resistant container. Talk to your doctor or pharmacist about how to dispose of the puncture-resistant container.

What special precautions should I follow?

Before receiving caplacizumab-yhdp,

tell your doctor and pharmacist if you are allergic to caplacizumab-yhdp, any other medications, or any of the ingredients in caplacizumab-yhdp injection. Ask your pharmacist for a list of the ingredients.
tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: apixaban (Eliquis), clopidogrel (Plavix), dabigatran (Pradaxa), dipyridamole (Persantine, in Aggrenox), edoxaban (Savaysa), enoxaparin (Lovenox), fondaparinux (Arixtra), heparin, prasugrel (Effient), rivaroxaban (Xarelto), ticagrelor (Brilinta), or warfarin (Coumadin, Jantoven). Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
tell your doctor if you have or have ever had hemophilia (a genetic disorder in which the body can’t stop bleeding properly) or other bleeding problems, or liver disease.
tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. If you become pregnant while receiving caplacizumab-yhdp, call your doctor.
if you are having surgery, including dental surgery, tell the doctor or dentist that you are using caplacizumab-yhdp. Your doctor or dentist may tell you not to use caplacizumab-yhdp for 7 days before the surgery.

References